• 2011 Program

• 2011 Speakers

PROGRAM QUESTIONS?

Robert Lee Kilpatrick
Partner

Phone:
+1.831.464.4230

15:00-18:30  Early Check-in & Registration - Foyer

Visit the registration desk to check in on Sunday, which allows you to jump-start your networking opportunities at the Welcome Reception. By registering early, you'll be able to collect your name badge, program, and handbag materials and avoid long lines on Monday morning.

17:30-18:30  Welcome Reception - Foyer

Connect with fellow delegates over drinks and appetizers on Sunday evening before BioPartnering Latin America begins.

08:30-17:00  Registration - Foyer

09:00-09:15  Welcome Address - Palm II & III

Latin America is increasingly important in the development of a global life science industry. Several countries are leading in the region: Brasil, Chile, Argentina, and Uruguay are centers of excellence in the areas of human and animal health, agriculture and foods, as well as energy. There is growing support being provided by national and regional governments, as well as leadership being provided by universities and academic research institutes. Large international businesses are discovering the wealth of talent in Latin America, and the region is beginning to network more with the rest of the world. Biominas and TVG are committed to the evolution of the life science sector in Latin America, and we have created this program, with input from many experienced people, to demonstrate the many opportunities for investment and economic diversification in this region. 

Chair: Mr. Eduardo Emrich Soares, Chief Executive Officer & President, Fundação Biominas Brasil
Speaker: Dr. Robert Lee Kilpatrick, Partner, TVG

09:15-10:00  Keynote Address - Palm II & III

Title: Latin America - Fiction or Reality?

Biotechnology may be finally becoming a reality in several countries of Latin America, and this is no accident since the region, lead by Brazil, Chile, Peru and Colombia, has definitely found the way to continuous economic growth. These nations are still far from being technological powerhouses, their bio industries are thin and not very well connected, but the respective governments of such nations have consistently indicated a will to innovate in many aspects of their healthy economies.

These markets, are, therefore, ready for the kind of rapid developments that biotechnology may bring in disparate fields such as renewable energy sources, sustainable agriculture, and the health care sector, among others. I will give several examples of current projects, both public and private, as well as PPPs, that are going on in Latin America, and I will also refer to the main hurdles that challenge such rapid progress in the region.

More importantly, I will highlight the need for radical changes and entirely new models to establish an indigenous biotechnological industry in this part of the world. In particular, I think that in medicine, for instance, the time is right to harness the immense power of a very strong scientific community in the region to translate cutting-edge knowledge from systems biology, for example, to develop an entirely new way to universal access to health care at very reduced costs. A global need, indeed.

Speaker: Dr. Rafael Rangel-Aldao, President & Chief Executive Officer of SummumNet and Professor of Simon Bolivar University, SummumNet

10:00-11:00  Leadership Session 1 | Business - Palm II & III

Title: Biobusiness in Latin America

With a growing population of nowadays 580 million people, Latin America faces major ongoing challenges. The region needs to maintain the growth rates simultaneously to the application of policies to mitigate commodity price volatility, to boost productivity and to improve social inclusion.

In this general context, it is an excellent moment to look for knowledge-based opportunities and it is for this reason that all countries have now different but active policies to promote and to enhance the developments of biotechnology in all its components.

Particularly, Mercosur countries are one of the most dynamics regions in the world in using agri-biotechnologies, considering the main bioengineering crops and the uses of animal health and reproductive biotechnologies.

In the area of biopharmaceutics, the region has all the spectra of biotechnologies available, from stem cells applications, recombinant human proteins production in different models, especially in animals, and there is an important list of developments and different trials with many promissory new drugs.

Distinguished invited panelists will share they present experiences and the evolution of relevant and successful biobusiness. They will describe the “genetics” and the “environment” which allow their companies to be leading in key sectors and they will present their own visions on the future of Latin America biotechnology presence in a global context.

Chair: Mr. Eduardo Emrich Soares, Chief Executive Officer & President, Fundação Biominas Brasil
Speaker: Dr. Susana Levy, Executive Manager, Research & Development Biotechnology, Biogenesis Bagó
Speaker: Dr. Jaderson Lima, Medical and Scientific Alliances Director, Sanofi Aventis
Speaker: Dr. Daniel Pagliano, Director, Institute of Applied Biosciences - Universidad de la Empresa (UDE)
Speaker: Dr. José Fernando Perez, Chief Executive Officer & President, Recepta Biopharma

11:00-11:30  Morning Coffee & Tea Break - Palm II & III

Enjoy a cup of coffee or tea and network with delegates.

11:00-18:00  Face-to-Face Meetings | powered by biopartnering.com™ - Palm I

All meetings scheduled through biopartnering.com will be held at the numbered tables in Palm I. Please visit the onsite Meeting & Message Desk for assistance.

11:30-12:30  Leadership Session 2 | Investment - Palm II & III

Title: Moving to a next level: Developing the Venture Capital Industry in Latin America

Venture Capital industry for life sciences is starting in Latin America. The first VC funds dedicated to the bio sector are now starting operations in the region, after dealing with many challenges in raising capital for funds, putting different investors together and developing their initial pipeline. Panelists will present their learnings in the process, business models and discuss mechanisms to faster the launch of new funds in the future. Also, participants will hear about opportunities and perspectives for venture capital dedicated to the life sciences industry in the next years.

Chair: Mr. Clovis Meurer, Vice President, ABVCAP (Brazilian Venture Capital Association)
Speaker: Dr. Gabriela Cezar, Managing Director, Burrill & Company
Speaker: Mr. Augusto Ferreira da Costa Neto, Analyst, Department of Investment in Funds, FINEP, The Brazilian Agency for Innovation
Speaker: Ms. Lisa Rhoads, Chief Executive Officer, Brazilian Biologics
Speaker: Mr. David Travesso Neto, Chief Executive Officer, FIR Capital Partners

12:30-14:00  Hot Buffet Lunch - Palm II & III

Refresh yourself with a delicious hot lunch buffet.

14:00-15:30  Podium Presentations - Palm II & III

In this dedicated presentation room, companies from around the world will introduce their companies, key technologies, products and clinical developments, as well as state their companies' partnering and financing goals.

14:00 Polypeptide Group - Denmark
14:15 DesignMedix Inc - USA
14:30 Genor BioPharma Co., Ltd. - China
14:45 Bureau of Innovation and Competitive Intelligence on Biotechnology - Brazil
15:00 Seva Engenharia Eletrônica S.A. - Brazil
15:15 Neoprospecta Pesquisa e Consultoria LTDA - Brazil

15:30-16:00  Coffee & Tea Break - Palm II & III

Enjoy a cup of coffee or tea and network with delegates.
 

16:00-17:00  Leadership Session 3 | Sebrae-MG - Palm II & III

Title: Point of Care Diagnostics

Chair: Mrs. Carla A Farias, Analyst, SEBRAE MG
Speaker: Dr. Eliane Lustosa Cabral Gomez, President , Labtest Diagnóstica
Speaker: Dr. Ashley Hockham, Business Development Manager, Innova Biosciences
Speaker: Mr. Gilton Martins, President, Prodimol Biotecnologia (Alere Group)
Speaker: Mrs. Liliana Perez, President, Brazilian Chamber of Laboratory Diagnosis, CBDL
Speaker: Dr. Alexander Stuck, Division Head, CSEM Muttenz

17:00-18:00  Leadership Session 4 | Brazilian Landscape - Palm II & III

Title: Launch of the 2011 Brazilian Life Sciences Industry Report

This session will host the launch of the 2011 Brazilian Life Sciences Industry Report, co-developed by Biominas Brasil and PwC. The study outlines the current status of the industry, analyzing four main innovation pillars: intellectual property and technology transfer, financing, public policies and human resources. Based on surveys with Chief Executive Officers and directors, a forecast was also developed and several issues have emerged that shall be tackled by the main stakeholders of this industry in order for Brazil to achieve its full potential. The panel will gather local entrepreneurs and companies to discuss the main findings of the study and the report will be distributed at the end.

All participants are invited to join us at a reception that will follow the session (18:00-19:30).

Chair: Mr. Eduardo Emrich Soares, Chief Executive Officer & President, Fundação Biominas Brasil
Chair: Ms. Eliane Kihara, Partner, PricewaterhouseCoopers LLP (PwC)
Speaker: Dr. Paulo Coutinho, Open Innovation Manager, BRASKEM
Speaker: Mr. Nelson Levy, Vice-President of Research & Development & IP, Bionext
Speaker: Mr. Eduardo Mello, Vice President of Operations, Brazil & Global Tree Improvement (FuturaGene/Suzano Papel e Celulose)
Speaker: Mr. Hugo Zanocchi, President, Inova Biotecnologia Saúde Animal Ltda.

18:00-19:30  Networking Reception - Foyer

Sponsored by: PwC

Please join us for a relaxing evening of casual networking over wine and delicious hors d'oeuvres at the Networking Reception.

08:30-12:00  Registration - Foyer

09:00-09:45  Keynote Address - Palm II & III

Title: Partnering with Eli Lilly - Extending External Innovation Partnering Strategies into Emerging Markets

Eli Lilly and Company is a global pharmaceutical company with extensive capabilities and expertise in the development of small and large molecule (e.g., antibodies, proteins, peptides) therapeutics. Lilly’s internal research concentrates mainly in the Endocrine/Metabolism, Neuroscience, Oncology, Musculoskeletal, Autoimmune and Cardiovascular therapeutic areas and enhances the productivity of its internal R&D efforts with cutting edge, innovative technologies and tools. Partnering and collaborations is a strategic growth imperative.

At Eli Lilly, we exploring novel partnership strategies across all stages of pharmaceutical research and development to work with outstanding partners around the globe to bring innovative medicines that improve patient outcomes to market. Eli Lilly’s Global External Research and Development (GER&D) Organization leads the identification and assessment of potential partnering efforts with external institutions and companies, performs technical and scientific assessments, and due diligences. GER&D is composed of experienced pharmaceutical scientists and clinicians who proactively scout and evaluate scientific innovation around the world to identify differentiated "first-in-class” and “best-in-class” molecules and technologies that match strategic needs across all Eli Lilly and Company functions and portfolios. GER&D has a global orientation in the pursuit of external scientific innovation, with geographically located personnel and numerous successful partnerships all around the world including Japan. Dr. Yetunde Taiwo, PhD, who leads GER&D efforts in support of Lilly's Emerging Market Business Unit, will provide insights into Lilly’s therapeutic areas of interest, and an overview of some of Lilly’s evolving, innovative, partnership strategies.

Speaker: Dr. Yetunde Taiwo, Senior Director of Global External Research & Development, Eli Lilly and Company

09:00-17:30  Face-to-Face Meetings | powered by biopartnering.com™ - Palm I

All meetings scheduled through biopartnering.com will be held at the numbered tables in Palm I. Please visit the onsite Meeting & Message Desk for assistance.

09:45-10:45  Leadership Session 5 | Funding - Palm II & III

Title: How to Finance Big/Strategic Projects in Life Sciences in Latin America?

- Funding the gaps in infrastructure, product development chain

- Private funding mechanisms to big projects

Chair: Mr. Pedro Palmeira, Head of Pharmaceutical Department, BNDES
Speaker: Mr. Guilherme Emrich, Chairman, Biomm
Speaker: Mr. Carlos Eduardo Moreira, General Manager, GE Healthcare Life Sciences
Speaker: Dr. Ogari Pacheco, President, Cristalia

10:45-11:15  Morning Coffee & Tea Break - Foyer

Enjoy a cup of coffee or tea and network with delegates.

11:15-11:40  Pfizer Company Presentation - Palm II & III

Title: Transformative R&D: Focus on Partnership & Innovation

Speaker: Dr. João Fittipaldi, Medical Director, Pfizer (Laboratórios Pfizer)

11:40-12:05  Merck Serono Company Presentation - Palm II & III

Title: Merck Millipore is the Ideal Partner to Life Sciences Companies

This presentation will provide an overview of technologies applied to bioprocesses that are useful for lab scale, pilot scale or industrial scale.

Intended to present new technologies that can make a major difference to speed up developments and process robustness.

Integrated portfolio of products and services that makes Merck Millipore the partner of choice for upstream, downstream and bioprocess controls for the life science industry.

Speaker: Mr. Roberto Takashi Uchimura, Technology Manager, Latin America, Merck Millipore

12:05-12:30  Merck Company Presentation - Palm II & III

Title: Partnering with Merck

Speaker: Dr. Reid Leonard, Executive Director, Merck & Co., Inc./MSD

12:30-14:00  Hot Buffet Lunch - Palm II & III

Continue your networking over a delicious buffet lunch.

14:00-14:25  GE Healthcare Company Presentation - Palm II & III

Speaker: Ms. Daniella Kranjac, Enterprise Solutions Business Development Director, Americas, GE Healthcare Life Sciences

14:25-14:50  Bristol-Myers Squibb Company Presentation - Palm II & III

Title: Becoming a Biopharma Leader: BioPharma Strategy Paving the Way to Discover, Develop and Deliver Innovative Medicines to Help Patients Prevail Over Serious Diseases

Our strategy uniquely combines the reach and resources of a major pharma company with the entrepreneurial spirit and agility of a successful biotech company. With this strategy, we focus on our customers’ needs, giving maximum priority to accelerating pipeline development, delivering sales growth and continuing to manage costs.

Speaker: Mr. Jorge Alves, New Products Associate Director, Bristol-Myers Squibb Brazil
Speaker: Ms. Elaine Rahal, Brazil Country Medical Director, Bristol-Myers Squibb Brazil

15:00-17:30  Podium Presentations - Palm II & III

In this dedicated presentation room, companies from around the world will introduce their companies, key technologies, products and clinical developments, as well as state their companies' partnering and financing goals.

15:00 Agência Intelecto – Núcleo de Inovação Tecnológica (UFU) - Brazil
15:15 Eprimecare Gestão de Cuidados em Saúde S/A - Brazil
15:30 PharmaEssentia Corporation - Taiwan
15:45 Bayer Pharma AG - Germany
16:00 Clarke, Modet & Co. - Brazil
16:15 Celer Biotecnologia S.A - Brazil
16:30 CTIT | UFMG (Federal University of Minas Gerais) - Brazil
16:45 Novasep - France
17:00 Hamilton Robotics - Brazil
17:15 RENORBIO - Brazil

17:30-18:30  Farewell Drinks Reception - Foyer

An opportunity to say goodbye to fellow delegates and begin planning for the 3rd Annual BioPartnering Latin America in 2012.